Matinas BioPharma Hldgs Stock (AMEX: MTNB)

Matinas BioPharma Hldgs (AMEX:MTNB) Stock, Quote.Headers.trade-ideas

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Labs

Biotech

News

Health Care

Movers

General

MTNB

Progress with Matinas BioPharma&#39;s MAT2203 for invasive fusarium infection. Clinical response achieved in patients resistant to other antifungals.

Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?

Penny Stocks

Small Cap

Intraday Update

Markets

Trading Ideas

ACNT

ARBB

ASST

BAOS

BCLI

BETS

BJDX

CHRS

CING

COIN

CYTK

ELTX

EWTX

FWBI

GDHG

HALL

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

IOVA

JTAI

JZXN

LIDR

MGAM

MOBX

MYND

NUKK

ONCT

ORGO

RPHM

SMFL

VLCN

VNCE

VRAX

WULF

Shares of  Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per share.

Reneo Pharmaceuticals shares climbed 13.6% to $1.59 on Wednesday.

Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Equities

Wednesday, Matinas BioPharma Holdings Inc (NASDAQ: MTNB) announced results from a series of in vivo studies demonstrating successful oral delivery of two lipid nanocrystal (LNC)-formulated small single-strand oligonucleotides targeting inflammatory cytokines TNFα and IL-17

Why Is Inflammatory Focused Matinas BioPharma Stock Trading Higher Today?

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

Litecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>) price has increased 3.58% over the past 24 hours to $65.12. Over the past week, LTC has experienced an uptick of over 5.0%, moving from $61.93 to its current price. As it stands right now, the coin's all-time high is $410.26. 
The chart below compares the price movement and volatility for Litecoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726758227_0.png" alt="price_chart" />
Litecoin's trading volume has climbed 22.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.38%. This brings the circulating supply to 74.99 million, which makes up an estimated 89.28% of its max supply of 84.00 million. According to our data, the current market cap ranking for LTC is #25 at $4.88 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726758227_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$LTC

Cryptocurrency Litecoin Rises More Than 3% In 24 hours

Over the past 24 hours, Aptos's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APT</a>) price rose 14.46% to $6.61. This continues its positive trend over the past week where it has experienced a 8.0% gain, moving from $6.12 to its current price. As it stands right now, the coin's all-time high is $19.92. 
The chart below compares the price movement and volatility for Aptos over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726758156_0.png" alt="price_chart" />
The trading volume for the coin has increased 106.0% over the past week while the overall circulating supply of the coin has increased 2.84% to over 500.08 million. The current market cap ranking for APT is #32 at $3.31 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726758157_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$APT

Cryptocurrency Aptos's Price Increased More Than 14% Within 24 hours

Over the past 24 hours, Wrapped stETH's (CRYPTO:WSTETH) price has risen 5.99% to $2,868.31. This continues its positive trend over the past week where it has experienced a 4.0% gain, moving from $2,758.98 to its current price. As it stands right now, the coin's all-time high is $7,256.02. 
The chart below compares the price movement and volatility for Wrapped stETH over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726758148_0.png" alt="price_chart" />
Wrapped stETH's trading volume has climbed 13.0% over the past week along with the circulating supply of the coin, which has increased 0.3%. This brings the circulating supply to 3.46 million. According to our data, the current market cap ranking for WSTETH is #14 at $9.91 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726758148_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Wrapped stETH Up More Than 5% In 24 hours

Over the past 24 hours, WETH's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WETH</a>) price has risen 5.67% to $2,428.12. This continues its positive trend over the past week where it has experienced a 4.0% gain, moving from $2,334.73 to its current price. As it stands right now, the coin's all-time high is $4,799.89. 
The chart below compares the price movement and volatility for WETH over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726758078_0.png" alt="price_chart" />
The trading volume for the coin has climbed 41.0% over the past week, moving opposite, directionally, with the overall circulating supply of the coin, which has decreased 1.28%. This brings the circulating supply to 2.92 million. According to our data, the current market cap ranking for WETH is #17 at $7.08 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726758078_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WETH

WETH Up More Than 5% In 24 hours

Making a noteworthy insider sell on September 18, Edmond Villani, Board Member at Cohen &amp; Steers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNS#NYSE">CNS</a>), is reported in the latest SEC filing.
What Happened: Villani's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001284812/000128481224000328//Archives/edgar/data/1284812/000128481224000328/0001284812-24-000328-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday unveiled the sale of 3,000 shares of Cohen &amp; Steers. The total transaction value is $290,280.
As of Thursday morning, Cohen &amp; Steers shares are down by 0.0%, currently priced at $95.37.
<h3>All You Need to Know About Cohen &amp; Steers</h3>
Cohen &amp; Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen &amp; Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.
<h3>Understanding the Numbers: Cohen &amp; Steers's Finances</h3>
Revenue Growth: Over the 3 months period, Cohen &amp; Steers showcased positive performance, achieving a revenue growth rate of 2.19% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 47.65%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Cohen &amp; Steers's EPS reflects a decline, falling below the industry average with a current EPS of 0.63.
</li>
</ul>
Debt Management: Cohen &amp; Steers's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 37.4 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 9.45 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 24.37, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001284812">Check Out The Full List Of Cohen &amp; Steers's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Edmond Villani Implements A Sell Strategy: Offloads $290K In Cohen & Steers Stock

KEYS

Keysight Expands PNA-X Vector Network Analyzer Portfolio With NA520xA, Offering Greater Versatility And Simplified Test Setups For Bi-Directional Noise Figure And Intermodulation Distortion Testing

On September 18, a recent SEC filing unveiled that Taylor Family Investments LLC, Director at Mission Produce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) made an insider sell.
What Happened: LLC opted to sell 297,072 shares of Mission Produce, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001802974/000145934924000002//Archives/edgar/data/1802974/000145934924000002/0001459349-24-000002-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The transaction's total worth stands at $3,884,632.
The latest market snapshot at Thursday morning reveals Mission Produce shares up by 0.07%, trading at $13.37.
<h3>All You Need to Know About Mission Produce</h3>
Mission Produce Inc is engaged in the business of producing and distributing avocados, serving retail, wholesale, and food service customers. Also, the company provides additional services like ripening, bagging, custom packing, and logistical management. The company's operating segments include Marketing and Distribution and International Farming and Blueberries. It generates maximum revenue from the Marketing and Distribution segment. The Marketing and Distribution segment sources fruit mainly from growers and then distributes fruit through a distribution network.
<h3>A Deep Dive into Mission Produce's Financials</h3>
Positive Revenue Trend: Examining Mission Produce's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.95% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a low gross margin of 11.42%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Mission Produce's EPS is below the industry average. The company faced challenges with a current EPS of 0.17. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Mission Produce's debt-to-equity ratio is below the industry average at 0.45, reflecting a lower dependency on debt financing and a more conservative financial approach.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 40.52 is lower than the industry average, implying a discounted valuation for Mission Produce's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.83, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Mission Produce's EV/EBITDA ratio of 12.97 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001802974">Check Out The Full List Of Mission Produce's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Mission Produce Insider Trades Send A Signal

Disclosed on September 18, Jay A Pack, Board Member at Mission Produce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: Pack's decision to sell 145,350 shares of Mission Produce was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001802974/000182587924000007//Archives/edgar/data/1802974/000182587924000007/0001825879-24-000007-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $1,922,893.
During Thursday's morning session, Mission Produce shares up by 0.07%, currently priced at $13.37.
<h3>Delving into Mission Produce's Background</h3>
Mission Produce Inc is engaged in the business of producing and distributing avocados, serving retail, wholesale, and food service customers. Also, the company provides additional services like ripening, bagging, custom packing, and logistical management. The company's operating segments include Marketing and Distribution and International Farming and Blueberries. It generates maximum revenue from the Marketing and Distribution segment. The Marketing and Distribution segment sources fruit mainly from growers and then distributes fruit through a distribution network.
<h3>Mission Produce: Delving into Financials</h3>
Revenue Growth: Mission Produce's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately 23.95%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 11.42%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Mission Produce exhibits below-average bottom-line performance with a current EPS of 0.17.
</li>
</ul>
Debt Management: Mission Produce's debt-to-equity ratio is below the industry average at 0.45, reflecting a lower dependency on debt financing and a more conservative financial approach.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 40.52 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.83 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 12.97 reflects market recognition of Mission Produce's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001802974">Check Out The Full List Of Mission Produce's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Mission Produce Board Member Sold $1.92M In Company Stock

It was reported on September 18, that MICHAEL HARTNETT, President and CEO at RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) executed a significant insider sell, according to an SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001324948/000159396824001207//Archives/edgar/data/1324948/000159396824001207/0001593968-24-001207-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that HARTNETT sold 12,503 shares of RBC Bearings. The total transaction amounted to $3,630,287. 
During Thursday's morning session, RBC Bearings shares down by 0.0%, currently priced at $292.16.
<h3>Discovering RBC Bearings: A Closer Look</h3>
RBC Bearings Inc is an international manufacturer and marketer of highly engineered precision bearings, components and essential systems for the industrial, defense and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The end market is the United States of America. The company has two reportable segments: Aerospace Defense segment represents the end markets for the company's highly engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and Industrial segment represents the end markets for the company's engineered bearings and precision components used in various industrial applications. It derives maximum revenue from Industrial Segment.
<h3>Financial Milestones: RBC Bearings's Journey</h3>
Revenue Growth: RBC Bearings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 4.96%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 45.29%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): RBC Bearings's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.92.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.42.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 43.03, RBC Bearings's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 5.41, RBC Bearings's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 20.42 reflects market recognition of RBC Bearings's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001324948">Check Out The Full List Of RBC Bearings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Selling: MICHAEL HARTNETT Unloads $3.63M Of RBC Bearings Stock

Sports fans can visit the Evergreen State's largest casino to register and enjoy an elevated sports wagering experience on mobile devices while on property
Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) ("Caesars") launched the Caesars Sportsbook Muckleshoot app, which is now accepting mobile sports bets at Muckleshoot Casino Resort in Auburn, Washington. Guests 21 and older who are interested in wagering on mobile devices can <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.caesars.com%2Fsportsbook-and-casino%2Fwa-ms%2Fget-the-app%2F&amp;esheet=54124397&amp;newsitemid=20240919791651&amp;lan=en-US&amp;anchor=download&amp;index=1&amp;md5=2c08b8ebb2f8e9fae8a6b5a395f171e5">download</a> the Caesars Sportsbook Muckleshoot app and must be physically present on the property at Muckleshoot to verify their registration for an account and place wagers during their visit, in accordance with state law.

Caesars Sportsbook Expands Sports Betting Offering In Washington State With Mobile Wagering Launch At Muckleshoot Casino Resort

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) against its key competitors in the Biotechnology industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>AbbVie Background</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc</td>
<td>64.53</td>
<td>50.28</td>
<td>6.22</td>
<td>18.4%</td>
<td>$5.0</td>
<td>$10.26</td>
<td>4.31%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>57.40</td>
<td>30.19</td>
<td>5.81</td>
<td>13.63%</td>
<td>$3.0</td>
<td>$5.15</td>
<td>20.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>30.15</td>
<td>4.45</td>
<td>9.66</td>
<td>5.19%</td>
<td>$1.76</td>
<td>$3.07</td>
<td>12.32%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>102.32</td>
<td>5.71</td>
<td>3.78</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>24.92</td>
<td>1.81</td>
<td>2.98</td>
<td>3.75%</td>
<td>$0.92</td>
<td>$1.92</td>
<td>0.36%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>20.81</td>
<td>3.60</td>
<td>6.06</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>15.74</td>
<td>2.68</td>
<td>6.44</td>
<td>5.04%</td>
<td>$0.39</td>
<td>$0.64</td>
<td>19.85%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>53.89</td>
<td>2.56</td>
<td>5.34</td>
<td>2.07%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>19.61%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>158.93</td>
<td>4.19</td>
<td>3.78</td>
<td>-10.6%</td>
<td>$-0.37</td>
<td>$0.97</td>
<td>9.34%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>36.10</td>
<td>4.82</td>
<td>5.81</td>
<td>2.66%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>30.37%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>166.68</td>
<td>11.07</td>
<td>8.12</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>2.09</td>
<td>1.63</td>
<td>63.42</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Halozyme Therapeutics Inc</td>
<td>24.15</td>
<td>27.27</td>
<td>9.34</td>
<td>39.91%</td>
<td>$0.14</td>
<td>$0.19</td>
<td>4.67%</td>
</tr>
<tr>
<td>Average</td>
<td>57.77</td>
<td>8.33</td>
<td>10.88</td>
<td>6.45%</td>
<td>$0.95</td>
<td>$2.01</td>
<td>28.79%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a detailed examination of AbbVie, we can deduce the following trends: 
<ul>
<li>
The Price to Earnings ratio of 64.53 for this company is 1.12x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 50.28 which exceeds the industry average by 6.04x.
</li>
<li>
With a relatively low Price to Sales ratio of 6.22, which is 0.57x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a higher Return on Equity (ROE) of 18.4%, which is 11.95% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
</li>
<li>
The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.0 Billion, which is 5.26x above the industry average, implying stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $10.26 Billion, which indicates 5.1x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 4.31% is significantly below the industry average of 28.79%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726758052_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing AbbVie against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
When evaluating the debt-to-equity ratio, AbbVie is in the middle position among its top 4 peers.
</li>
<li>
The company maintains a moderate level of debt relative to its equity with a debt-to-equity ratio of 10.42, suggesting a relatively balanced financial structure.
</li>
</ul>
<h3>Key Takeaways</h3>
For AbbVie, the PE, PB, and PS ratios are all high compared to its peers in the Biotechnology industry, indicating potentially overvalued stock. On the other hand, AbbVie's high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency relative to industry peers. However, the low revenue growth rate may raise concerns about the company's future performance compared to its competitors in the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry

On September 19, a recent SEC filing unveiled that Samuel Kapourales, Director at Energy Servs of America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESOA#NASDAQ">ESOA</a>) made an insider sell.
What Happened: Kapourales's recent move involves selling 50,000 shares of Energy Servs of America. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001357971/000110465924101199//Archives/edgar/data/1357971/000110465924101199/0001104659-24-101199-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value is $505,000.
Energy Servs of America's shares are actively trading at $10.71, experiencing a up of 7.1% during Thursday's morning session.
<h3>Get to Know Energy Servs of America Better</h3>
Energy Services of America Corporation is engaged in providing contracting services for energy-related companies. The company is predominantly engaged in the construction, replacement, and repair of natural gas pipelines and storage facilities for utility companies and private natural gas companies. It services the gas, petroleum, power, chemical, and automotive industries and does incidental work such as water and sewer projects. Energy Service's other services include liquid pipeline construction, pump station construction, production facility construction, water and sewer pipeline installations, various maintenance and repair services, and other services related to pipeline construction.
<h3>A Deep Dive into Energy Servs of America's Financials</h3>
Revenue Growth: Over the 3 months period, Energy Servs of America showcased positive performance, achieving a revenue growth rate of 0.46% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 17.82%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Energy Servs of America's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.06.
</li>
</ul>
Debt Management: Energy Servs of America's debt-to-equity ratio surpasses industry norms, standing at 0.66. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Energy Servs of America's P/E ratio of 6.9 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.47 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Energy Servs of America's EV/EBITDA ratio, lower than industry averages at 4.2, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001357971">Check Out The Full List Of Energy Servs of America's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ESOA

Sell Alert: Samuel Kapourales Cashes Out $505K In Energy Servs of America Stock

On September 18, it was revealed in an SEC filing that Matthew E Korenberg, President &amp; COO at Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000886163/000200101124000082//Archives/edgar/data/886163/000200101124000082/0002001011-24-000082-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Korenberg, President &amp; COO at Ligand Pharmaceuticals, a company in the Health Care sector, just exercised stock options worth 5,774 shares of LGND stock with an exercise price of $58.49.
Ligand Pharmaceuticals shares are currently trading down by 0.0%, with a current price of $103.68 as of Thursday morning. This brings the total value of Korenberg's 5,774 shares to $260,951.
<h3>Discovering Ligand Pharmaceuticals: A Closer Look</h3>
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
<h3>Breaking Down Ligand Pharmaceuticals's Financial Performance</h3>
Positive Revenue Trend: Examining Ligand Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 57.52% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 93.0%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Ligand Pharmaceuticals's EPS reflects a decline, falling below the industry average with a current EPS of -2.88.
</li>
</ul>
Debt Management: Ligand Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 44.5 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 13.96 is above industry norms, reflecting an elevated valuation for Ligand Pharmaceuticals's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Ligand Pharmaceuticals's EV/EBITDA ratio, surpassing industry averages at 18.86, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000886163">Check Out The Full List Of Ligand Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LGND

Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K

Stifel analyst Matthew Smith maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Buy and raises the price target from $70 to $82.

Price Target

Analyst Ratings

Stifel Maintains Buy on General Mills, Raises Price Target to $82

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) against its key competitors in the Semiconductors &amp; Semiconductor Equipment industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Advanced Micro Devices Background</h3>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications, among others. AMD's traditional strength was in central processing units, CPUs, and graphics processing units, or GPUs, used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array, or FPGA, leader Xilinx to diversify its business and augment its opportunities in key end markets such as the data center and automotive.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced Micro Devices Inc</td>
<td>176.54</td>
<td>4.25</td>
<td>10.44</td>
<td>0.47%</td>
<td>$1.12</td>
<td>$2.86</td>
<td>8.88%</td>
</tr>
<tr>
<td>NVIDIA Corp</td>
<td>53.15</td>
<td>47.82</td>
<td>29.31</td>
<td>30.94%</td>
<td>$19.71</td>
<td>$22.57</td>
<td>122.4%</td>
</tr>
<tr>
<td>Taiwan Semiconductor Manufacturing Co Ltd</td>
<td>29.55</td>
<td>7.30</td>
<td>11.35</td>
<td>6.67%</td>
<td>$474.12</td>
<td>$358.12</td>
<td>40.07%</td>
</tr>
<tr>
<td>Broadcom Inc</td>
<td>130.59</td>
<td>11.50</td>
<td>16.01</td>
<td>-2.77%</td>
<td>$6.39</td>
<td>$8.36</td>
<td>47.27%</td>
</tr>
<tr>
<td>Qualcomm Inc</td>
<td>21.52</td>
<td>7.60</td>
<td>5.09</td>
<td>8.67%</td>
<td>$2.87</td>
<td>$5.22</td>
<td>11.15%</td>
</tr>
<tr>
<td>Texas Instruments Inc</td>
<td>34.78</td>
<td>10.65</td>
<td>11.44</td>
<td>6.59%</td>
<td>$1.76</td>
<td>$2.21</td>
<td>-15.65%</td>
</tr>
<tr>
<td>ARM Holdings PLC</td>
<td>341.98</td>
<td>25.61</td>
<td>41.46</td>
<td>4.07%</td>
<td>$0.23</td>
<td>$0.91</td>
<td>39.11%</td>
</tr>
<tr>
<td>Analog Devices Inc</td>
<td>67.06</td>
<td>3.14</td>
<td>11.46</td>
<td>1.11%</td>
<td>$1.04</td>
<td>$1.31</td>
<td>-24.84%</td>
</tr>
<tr>
<td>Intel Corp</td>
<td>86.54</td>
<td>0.77</td>
<td>1.60</td>
<td>-1.46%</td>
<td>$0.86</td>
<td>$4.55</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Monolithic Power Systems Inc</td>
<td>102.40</td>
<td>19.10</td>
<td>22.20</td>
<td>4.66%</td>
<td>$0.13</td>
<td>$0.28</td>
<td>15.03%</td>
</tr>
<tr>
<td>Microchip Technology Inc</td>
<td>30.42</td>
<td>6.40</td>
<td>6.33</td>
<td>1.98%</td>
<td>$0.41</td>
<td>$0.74</td>
<td>-45.76%</td>
</tr>
<tr>
<td>ON Semiconductor Corp</td>
<td>16.09</td>
<td>3.63</td>
<td>3.99</td>
<td>4.11%</td>
<td>$0.58</td>
<td>$0.78</td>
<td>-17.15%</td>
</tr>
<tr>
<td>First Solar Inc</td>
<td>21.59</td>
<td>3.57</td>
<td>6.91</td>
<td>4.94%</td>
<td>$0.48</td>
<td>$0.5</td>
<td>24.65%</td>
</tr>
<tr>
<td>STMicroelectronics NV</td>
<td>7.36</td>
<td>1.42</td>
<td>1.71</td>
<td>3.51%</td>
<td>$1.31</td>
<td>$1.15</td>
<td>-25.29%</td>
</tr>
<tr>
<td>GLOBALFOUNDRIES Inc</td>
<td>26.84</td>
<td>1.92</td>
<td>3.17</td>
<td>1.38%</td>
<td>$0.56</td>
<td>$0.4</td>
<td>-11.54%</td>
</tr>
<tr>
<td>United Microelectronics Corp</td>
<td>12.62</td>
<td>1.88</td>
<td>2.95</td>
<td>3.76%</td>
<td>$27.9</td>
<td>$19.98</td>
<td>0.89%</td>
</tr>
<tr>
<td>ASE Technology Holding Co Ltd</td>
<td>19.16</td>
<td>2.19</td>
<td>1.14</td>
<td>2.62%</td>
<td>$26.08</td>
<td>$23.07</td>
<td>2.91%</td>
</tr>
<tr>
<td>Skyworks Solutions Inc</td>
<td>19.87</td>
<td>2.42</td>
<td>3.55</td>
<td>1.9%</td>
<td>$0.25</td>
<td>$0.36</td>
<td>-15.47%</td>
</tr>
<tr>
<td>Universal Display Corp</td>
<td>43.86</td>
<td>6.35</td>
<td>15.63</td>
<td>3.47%</td>
<td>$0.07</td>
<td>$0.12</td>
<td>8.15%</td>
</tr>
<tr>
<td>MACOM Technology Solutions Holdings Inc</td>
<td>101.02</td>
<td>6.68</td>
<td>10.73</td>
<td>1.88%</td>
<td>$0.04</td>
<td>$0.1</td>
<td>28.25%</td>
</tr>
<tr>
<td>Lattice Semiconductor Corp</td>
<td>38.29</td>
<td>10.27</td>
<td>11.54</td>
<td>3.28%</td>
<td>$0.04</td>
<td>$0.08</td>
<td>-34.72%</td>
</tr>
<tr>
<td>Cirrus Logic Inc</td>
<td>22.84</td>
<td>3.55</td>
<td>3.71</td>
<td>2.3%</td>
<td>$0.07</td>
<td>$0.19</td>
<td>17.98%</td>
</tr>
<tr>
<td>Average</td>
<td>58.45</td>
<td>8.75</td>
<td>10.54</td>
<td>4.46%</td>
<td>$26.9</td>
<td>$21.48</td>
<td>7.93%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By conducting an in-depth analysis of Advanced Micro Devices, we can identify the following trends: 
<ul>
<li>
Notably, the current Price to Earnings ratio for this stock, 176.54, is 3.02x above the industry norm, reflecting a higher valuation relative to the industry.
</li>
<li>
With a Price to Book ratio of 4.25, significantly falling below the industry average by 0.49x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The Price to Sales ratio is 10.44, which is 0.99x the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
With a Return on Equity (ROE) of 0.47% that is 3.99% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.12 Billion is 0.04x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $2.86 Billion, which indicates 0.13x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 8.88% is notably higher compared to the industry average of 7.93%, showcasing exceptional sales performance and strong demand for its products or services.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726758041_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By analyzing Advanced Micro Devices in relation to its top 4 peers based on the Debt-to-Equity ratio, the following insights can be derived:
<ul>
<li>
Compared to its top 4 peers, Advanced Micro Devices has a stronger financial position indicated by its lower debt-to-equity ratio of 0.04.
</li>
<li>
This suggests that the company relies less on debt financing and has a more favorable balance between debt and equity, which can be seen as a positive attribute by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Advanced Micro Devices, the PE ratio is high compared to peers, indicating potentially overvalued stock. The PB and PS ratios are low, suggesting undervaluation relative to industry competitors. In terms of ROE, EBITDA, gross profit, and revenue growth, Advanced Micro Devices lags behind its peers, indicating weaker financial performance and growth prospects within the Semiconductors &amp; Semiconductor Equipment industry.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comparing Advanced Micro Devices With Industry Competitors In Semiconductors &amp; Semiconductor Equipment Industry

A substantial insider activity was disclosed on September 19, as ONeil, President and COO at Kirby (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEX#NYSE">KEX</a>), reported the exercise of a large sell of company stock options.
What Happened: ONeil, President and COO at Kirby, made a strategic move by exercising stock options for 10,698 shares of KEX as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000056047/000095017024108012//Archives/edgar/data/56047/000095017024108012/0000950170-24-108012-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $508,796.
As of Thursday morning, Kirby shares are down by 0.0%, with a current price of $123.06. This implies that ONeil's 10,698 shares have a value of $508,796.
<h3>About Kirby</h3>
Kirby Corp is a domestic tank barge operator, transporting bulk liquid products throughout three United States coasts. The Company transports petrochemicals, black oil, refined petroleum products, and agricultural chemicals by tank barge. The Company conducts operations in two reportable business segments: The Marine transportation segment which provides marine transportation services, operating tank barges and towing vessels transporting bulk liquid products, and the Distribution and services segment, which provides after-market service, and genuine replacement parts for engines, transmissions, reduction gears, and power generation equipment used in oil and gas and commercial and industrial applications. The company's revenue is generated from the Marine Transportation segment.
<h3>Unraveling the Financial Story of Kirby</h3>
Revenue Growth: Kirby's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.07%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 25.56%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Kirby's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.44.
</li>
</ul>
Debt Management: Kirby's debt-to-equity ratio is below the industry average at 0.38, reflecting a lower dependency on debt financing and a more conservative financial approach.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 26.13 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 2.28 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Kirby's EV/EBITDA ratio of 12.89 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000056047">Check Out The Full List Of Kirby's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Unloading: Christian ONeil Sells Options, Realizes $508K

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) and its primary competitors in the Household Products industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Procter &amp; Gamble Background</h3>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procter &amp; Gamble Co</td>
<td>28.89</td>
<td>8.26</td>
<td>5.12</td>
<td>6.2%</td>
<td>$4.85</td>
<td>$10.18</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Colgate-Palmolive Co</td>
<td>30.08</td>
<td>685.42</td>
<td>4.26</td>
<td>414.16%</td>
<td>$1.25</td>
<td>$3.07</td>
<td>4.89%</td>
</tr>
<tr>
<td>Kimberly-Clark Corp</td>
<td>20.88</td>
<td>41.85</td>
<td>2.36</td>
<td>49.91%</td>
<td>$0.84</td>
<td>$1.81</td>
<td>-2.05%</td>
</tr>
<tr>
<td>Church &amp; Dwight Co Inc</td>
<td>31.67</td>
<td>5.83</td>
<td>4.23</td>
<td>5.79%</td>
<td>$0.4</td>
<td>$0.71</td>
<td>3.92%</td>
</tr>
<tr>
<td>Clorox Co</td>
<td>72.65</td>
<td>61.73</td>
<td>2.88</td>
<td>103.1%</td>
<td>$0.35</td>
<td>$0.88</td>
<td>-5.75%</td>
</tr>
<tr>
<td>Reynolds Consumer Products Inc</td>
<td>18.37</td>
<td>3.24</td>
<td>1.78</td>
<td>4.82%</td>
<td>$0.17</td>
<td>$0.26</td>
<td>-1.06%</td>
</tr>
<tr>
<td>WD-40 Co</td>
<td>51.52</td>
<td>15.99</td>
<td>6.20</td>
<td>9.02%</td>
<td>$0.03</td>
<td>$0.08</td>
<td>9.4%</td>
</tr>
<tr>
<td>Central Garden &amp; Pet Co</td>
<td>15.23</td>
<td>1.40</td>
<td>0.67</td>
<td>5.14%</td>
<td>$0.14</td>
<td>$0.32</td>
<td>-2.63%</td>
</tr>
<tr>
<td>Spectrum Brands Holdings Inc</td>
<td>23.43</td>
<td>1.24</td>
<td>1.23</td>
<td>0.28%</td>
<td>$0.08</td>
<td>$0.3</td>
<td>5.97%</td>
</tr>
<tr>
<td>Energizer Holdings Inc</td>
<td>208.50</td>
<td>16.98</td>
<td>0.73</td>
<td>-27.84%</td>
<td>$0.01</td>
<td>$0.28</td>
<td>0.29%</td>
</tr>
<tr>
<td>Oil-Dri Corp of America</td>
<td>11.68</td>
<td>2.44</td>
<td>1.60</td>
<td>3.9%</td>
<td>$0.02</td>
<td>$0.03</td>
<td>1.28%</td>
</tr>
<tr>
<td>Average</td>
<td>48.4</td>
<td>83.61</td>
<td>2.59</td>
<td>56.83%</td>
<td>$0.33</td>
<td>$0.77</td>
<td>1.43%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By conducting an in-depth analysis of Procter &amp; Gamble, we can identify the following trends: 
<ul>
<li>
A Price to Earnings ratio of 28.89 significantly below the industry average by 0.6x suggests undervaluation. This can make the stock appealing for those seeking growth.
</li>
<li>
With a Price to Book ratio of 8.26, significantly falling below the industry average by 0.1x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The stock's relatively high Price to Sales ratio of 5.12, surpassing the industry average by 1.98x, may indicate an aspect of overvaluation in terms of sales performance.
</li>
<li>
With a Return on Equity (ROE) of 6.2% that is 50.63% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.
</li>
<li>
The company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $4.85 Billion, which is 14.7x above the industry average, indicating stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $10.18 Billion, which indicates 13.22x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of -0.1% compared to the industry average of 1.43%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726758031_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By evaluating Procter &amp; Gamble against its top 4 peers in terms of the Debt-to-Equity ratio, the following observations arise:
<ul>
<li>
Compared to its top 4 peers, Procter &amp; Gamble has a stronger financial position indicated by its lower debt-to-equity ratio of 0.67.
</li>
<li>
This suggests that the company relies less on debt financing and has a more favorable balance between debt and equity, which can be seen as a positive attribute by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Procter &amp; Gamble, the PE and PB ratios are low compared to peers in the Household Products industry, indicating potential undervaluation. However, the high PS ratio suggests that the stock may be overvalued based on revenue. In terms of profitability, the low ROE and revenue growth, along with high EBITDA and gross profit, indicate mixed performance compared to industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Procter &amp; Gamble Against Peers In Household Products Industry

Over the past 24 hours, Bitcoin Cash's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>) price has risen 9.81% to $339.63. This continues its positive trend over the past week where it has experienced a 3.0% gain, moving from $331.09 to its current price. As it stands right now, the coin's all-time high is $3,785.82. 
The chart below compares the price movement and volatility for Bitcoin Cash over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726758007_0.png" alt="price_chart" />
The trading volume for the coin has increased 98.0% over the past week. while the overall circulating supply of the coin has decreased 0.22% This puts its current circulating supply at an estimated 94.11% of its max supply, which is 21.00 million. The current market cap ranking for BCH is #19 at $6.71 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726758007_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$BCH

Bitcoin Cash Rises More Than 9% In 24 hours

Werner Enterprises&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wern#NASDAQ">WERN</a>) top line is grappling with a freight market downturn, hurting the company&#39;s prospects. Elevated operating expenses are challenging the company&#39;s financial stability. Escalated labor and fuel costs are hurting WERN&#39;s bottom line, making it an unattractive choice for investors&#39; portfolios.
Let&#39;s delve deeper.
<h2>WERN: Risks to Watch</h2>
Southward Earnings Estimate Revision:The Zacks Consensus Estimate for current-quarter earnings has been revised 33.3% downward in the past 60 days. For the current year, the consensus mark for earnings has moved 26% south in the same time frame. The unfavorable estimate revisions indicate brokers&#39; lack of confidence in the stock.
Weak Zacks Rank: Werner Enterprises currently carries a Zacks Rank #5 (Strong Sell).
Unimpressive Price Performance: WERN shares have declined 7% in the past year against the industry&#39;s 0.2% rise.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/f1/78379.jpg?v=444018168" />
Image Source: Zacks Investment Research
Bearish Industry Rank: The industry to which Werner Enterprises belongs currently has a Zacks Industry Rank of 222 (out of 251). Such an unfavorable rank places it in the bottom 11% of Zacks Industries.Studies show that 50% of a stock price movement is directly related to the performance of the industry group it belongs to.
A mediocre stock within a strong group is likely to outclass a robust stock in a weak industry. Reckoning the industry&#39;s performance becomes imperative.
High Costs:&nbsp; High operating expenses are hurting WERN&#39;sbottom line, challenging its financial stability. The surge in operating expenses was caused by increased labor and fuel costs. In the second quarter of 2024, labor costs, comprising salaries and benefits, accounting for 35.1% of the total operating expenses, amounted to $741.2 million. Fuel costs totaled $72 million.
The freight market downturn does not bode well for the company&#39;s prospects. As a result, the top line fell by 6% year over year.
The persistent driver crisis in the trucking industry is worsening supply-chain challenges across the United States. Driver scarcity issues limit trucking capacity, making it difficult for trucking companies like WERN. American Trucking Associations&#39; chief economist, Bob Costello, expects the trucking industry to be short of more than&nbsp;160,000 drivers by 2030.
<h2>Stocks to Consider</h2>
Some better-ranked stocks for investors&#39; consideration in the Zacks Transportation sector include C.H. Robinson Worldwide (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrw#NASDAQ">CHRW</a>) and Westinghouse Air Brake Technologies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wab#NYSE">WAB</a>).
C.H. Robinson Worldwide currently sports a Zacks Rank #1 (Strong Buy).&nbsp;CHRW has an expected earnings growth rate of 25.2% for the current year.
The company has an impressive earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed once, delivering an average surprise of 7.3%. Shares of CHRW have risen 14.2% in the past year.
WAB carries a Zacks Rank #2 (Buy) at present and has an expected earnings growth rate of 26% for the current year.
The company has a discouraging track record with respect to the earnings surprise, having surpassed the Zacks Consensus Estimate in three of the trailing four quarters. The average beat is 11.8%. Shares of WAB have climbed 61% in the past year.
<a href="https://www.zacks.com/stock/news/2338348/here-s-why-investors-should-give-wern-stock-a-miss-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2338348">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Mid Cap

CHRW

WERN

Here's Why Investors Should Give WERN Stock a Miss Now

Macro Economic Events

Market Summary

Economics

$BTC

Benzinga Market Summary: Stocks Across Sectors Rise On Rate Cut, Gold And Bitcoin Gain

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/stock-types/penny-stocks/">Penny stocks</a> to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word &ldquo;potential.&rdquo; That doesn&rsquo;t mean guaranteed &ndash; not by a long shot.



Indeed, let&rsquo;s talk about the dangers of this market subsector. While the low price of these securities tend to make them move on little (or even no) news, the opposite is also true. So, for example, if you put $10,000 into a 2-cent stock and it drops to 1 cent, guess what? You now have a position worth only $5,000.



That can be devastating for many investors who are lured into the arena on the promise of quick riches. Riches can happen, don&rsquo;t get me wrong. However, you&rsquo;re more likely to lose than to win statistically. Therefore, tight money management is an absolute must. If you can handle the heat, these penny stocks to buy might be right for you.



<h2> Lilium (LILM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/09/lilm-stock-1-300x169.jpg" alt="The website for Lilium (LILM) is displayed on a smartphone screen."><div>Source: T. Schneider / Shutterstock.com</div></div>A specialist in the field of electric vertical takeoff and landing (eVTOL) aircraft, Lilium (NASDAQ:<a href="https://investorplace.com/stock-quotes/lilm-stock-quote/">LILM</a>) understandably ranks among the most popular penny stocks to buy. That&rsquo;s evidenced by the consensus <a href="https://www.tipranks.com/stocks/lilm/forecast">moderate buy</a> view among Wall Street analysts. Further, the average price target calls for a rise to $2, which implies roughly 52% upside potential.



So, what&rsquo;s not to love? It&rsquo;s volatile. Sure, LILM stock gained about 12% of equity value recently. With that, it&rsquo;s up over 33% in the trailing 52 weeks. However, since making its public market debut, shares have lost 88%. That&rsquo;s not a great sign for the company obviously. At the same time, it&rsquo;s not as if the eVTOL sector is lighting up the board.



Further, another risk factor to keep in mind is that Lilium is a pre-revenue enterprise. That said, there is anticipated financial momentum. For fiscal 2024, covering experts believe that Lilium will post a loss of 59 cents per share, an improvement over last year&rsquo;s loss of 77 cents.



Most importantly, in fiscal 2025, they project revenue of $56.99 million. It&rsquo;s risky but that&rsquo;s the compelling nature of penny stocks to buy.



<h2>BlackSky Technology (BKSY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/satellite-maxr-300x169.jpg" alt="(RKLB stock, space stocks) satellite over the Earth"><div>Source: Andrzej Puchta / Shutterstock.com</div></div>Based in Herndon, Virginia, BlackSky Technology (NYSE:<a href="https://investorplace.com/stock-quotes/bksy-stock-quote/">BKSY</a>) falls under the scientific and technical instruments category. <a href="https://finance.yahoo.com/quote/BKSY/profile">Per its public profile</a>, BlackSky provides geospatial intelligence, imagery and related data analytic products and services and mission systems. These systems include the development, integration and operation of satellite and ground systems for government and commercial customers in North America and other international markets.



As part of the burgeoning space economy, it&rsquo;s easy to see why BKSY is one of the penny stocks to buy. Financially, while the company has been all over the map in terms of earnings performance, it&rsquo;s been known to knock some balls out of the park. For example, it delivered earnings per share of one cent in the third quarter of last year. In contrast, the expected target was a loss of 12 cents.



For fiscal 2024, experts anticipate a loss of 33 cents per share on revenue of $110.76 million. That&rsquo;s a big step forward in terms of the top line, which was only $94.49 million in 2023. For those that can handle volatility risk, BKSY should be on your radar.



<h2>Avino Silver &amp; Gold (ASM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/silver-mining-1600-300x169.jpg" alt="Macro of silver"><div>Source: Phawat / Shutterstock.com</div></div>Operating in the basic materials sector, Avino Silver &amp; Gold (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/asm-stock-quote/">ASM</a>) features a business that&rsquo;s self-explanatory. It engages in the acquisition, exploration and advancement of mineral properties. Primarily, it explores for silver, gold and copper deposits. The former two assets naturally carry monetary policy implications as they&rsquo;re traditionally considered inflation hedges. The latter is a key metal to target if the global economy improves.



One factor that makes ASM a robust candidate for penny stocks to buy is the fear trade. With economic concerns juxtaposed with geopolitical flashpoints, investors have much to fret about. Gold can help but gold is also inconvenient to own. If you have a security like ASM stock, however, you can potentially enjoy secondary exposure to the yellow metal.



Even better, for fiscal 2024, analysts anticipate that EPS will hit four cents on revenue of $59.53 million. That&rsquo;s up from a breakeven year in 2023 and sales of $43.89 million. Looking out to fiscal 2025, EPS could rise to 7 cents on sales of $69.03 million.



<h2>Hookipa Pharma (HOOK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Operating in the broader healthcare space, Hookipa Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/hook-stock-quote/">HOOK</a>) falls under the biotechnology umbrella. <a href="https://finance.yahoo.com/quote/HOOK/profile">Per its corporate profile</a>, Hookipa is a clinical-stage enterprise that is developing immunotherapeutics targeting infectious diseases and cancers based on the company&rsquo;s proprietary arenavirus platform. Its lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab, which is in a Phase 2 trial.



Notably, Hookipa enjoys a collaboration with Gilead Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a>). This effort focuses on preclinical research programs to evaluate potential vaccine products for the treatment, diagnosis or prevention of the hepatitis B virus. Hookipa features variable earnings performances. However, in Q1 2024, it posted EPS of 11 cents against an expected loss per share of 10 cents.



For fiscal 2024, experts project a loss per share of 34 cents on revenue of $55.47 million. That&rsquo;s a massive improvement over last year&rsquo;s loss of 86 cents per share on sales of only $20.13 million. Therefore, it could be one of the worthwhile penny stocks to buy. Do note, though, that HOOK is volatile, losing 46% in the past 52 weeks.



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/kscp-stock-300x169.png" alt="An image of a Knightscope, Inc. (KSCP) robot in a parking garage"><div>Source: Sundry Photography / Shutterstock.com</div></div>An enticing (albeit extremely risky) idea for penny stocks to buy, Knightscope (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a>) deserves a look for anyone with some pocket change they want to use rather than throwing it in the wishing fountain. Specializing in autonomous security robots (ASRs), Knightscope could potentially change the game regarding security and law enforcement. Essentially, the company deploys robots as front-line security patrol operators.



This directive features myriad advantages over the traditional deployment of human officers. First and foremost, Knightscope addresses the safety concern. In a volatile situation, it&rsquo;s usually better to send a robot in because it&rsquo;s replaceable. Second, robots being non-human can sidestep the sometimes tricky situation involving security forces and community interactions.



Financially, Knightscope&rsquo;s performances are all over the map. However, in fiscal 2024, analysts anticipate the stats to tighten up. The company could generate a loss of 19 cents per share on revenue of $15.9 million. That&rsquo;s a big improvement over last year&rsquo;s results of a loss of 34 cents on sales of $12.8 million. Again, it&rsquo;s risky but Ascendiant&rsquo;s Edward Woo rates it a &ldquo;buy&rdquo; with a <a href="https://www.tipranks.com/stocks/kscp/forecast">$4.25 price target</a>.



<h2>Arqit Quantum (ARQQ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/06/cybersecurity-stocks-300x169.jpg" alt="A man sitting in front of a computer"><div>Source: Shutterstock</div></div>Based in London, U.K., Arqit Quantum (NASDAQ:<a href="https://investorplace.com/stock-quotes/arqq-stock-quote/">ARQQ</a>) falls under the infrastructure software category. <a href="https://finance.yahoo.com/quote/ARQQ/profile/">According to its public profile</a>, the company provides cybersecurity services through satellite and terrestrial platforms. It offers <a href="https://arqit.uk">QuantumCloud</a>, a Platform as a Service (PaaS) that allegedly creates unbreakable software encryption keys. Thus, it&rsquo;s a marriage of two compelling industries: cybersecurity and quantum computing.



Naturally, ARQQ makes an enticing case for penny stocks to buy due to the underlying relevance. It&rsquo;s not just about burgeoning interest in anything quantum related. Rather, the threat of digital hacks and breaches is only rising. It seems like every year, some major enterprise or organization suffers a significant compromising of its data, impacting both the business and its customers.



Cynically, then, Arqit benefits from a potentially permanent bullish narrative. How does that translate on paper? For fiscal 2024, experts believe the company will post a loss per share of 12 cents on revenue of $20.04 million. Last year, the company&rsquo;s results sat at a loss of 33 cents on sales of $693,000.



<h2>Matinas BioPharma (MTNB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div>Headquartered in Bedminster, New Jersey, Matinas BioPharma (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/mtnb-stock-quote/">MTNB</a>) also falls under the biotechnology umbrella. <a href="https://finance.yahoo.com/quote/MTNB/profile">According to its corporate profile</a>, Matinas is a clinical-stage enterprise that identifies and develops pharmaceutical products using its lipid nanocrystal (<a href="https://investorplace.com/stock-quotes/lnc-stock-quote/">LNC</a>) platform technology. This innovation allows for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins and peptides.



Currently, the company&rsquo;s <a href="https://www.matinasbiopharma.com/lnc-technology/mat2203-expanded-access-policy#:~:text=One%20of%20the%20Company's%20lead,(LNC)%20platform%20delivery%20technology.">lead product candidate is MAT2203</a>, an oral formulation that is currently in Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis. The drug candidate also aims to prevent invasive fungal infections in patients due to immunosuppressive therapy. Analysts rate shares a <a href="https://www.tipranks.com/stocks/mtnb/forecast">consensus moderate buy</a> with an 80-cent price target, implying almost 364% upside potential.



Of course, with such a massive profit target, you&rsquo;ve got to expect wild volatility. And that&rsquo;s the case with MTNB stock. Since the start of the year, shares lost 25% of equity value. In the past 52 weeks, they&rsquo;re down nearly 61%.



Still, if the clinical trials evolve successfully, MTNB could be huge. It&rsquo;s one of the penny stocks to buy (or at least to watch).



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/penny-stock-sleepers-7-under-the-radar-gems-ready-to-launch/">Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Matinas BioPharma (MTNB – Research Report). The associated price target r...

Buy Rating Affirmed for Matinas BioPharma's Drug MAT2203 Amid Successful Treatments and Pivotal Phase 3 Study

Matinas Biopharma Q2 2024 Earnings Preview

Matinas Biopharma GAAP EPS of -$0.02 beats by $0.01

Matinas BioPharma Holdings, Inc. 2024 Q2 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Matinas BioPharma Hldgs (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mtnb-stock-quote/">MTNB</a>) just reported results for the second quarter of 2024.<ul><li>Matinas BioPharma Hldgs reported earnings per share of -2 cents. This met the analyst estimate for EPS of -2 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mtnb-stock-earnings-matinas-biopharma-hldgs-for-q2-of-2024/">MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024

Matinas BioPharma (MTNB) has provided an update. The Company has updated its corporate presentation for use at upcoming conferences and investor me...

Matinas BioPharma Releases Updated Corporate Presentation

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price...

Buy Rating Affirmed: Matinas BioPharma's Solid Financials and Promising Drug Development

These are the upcoming stock splits for the week of September 2 to September 6, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a c...

Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested

ARQQ

BKSY

DPRO

GILD

HOOK

KSCP

LILM

WRIV

Press Releases

Matinas BioPharma Prices $10 Million Registered Direct Offering

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

Matinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Matinas BioPharma Hldgs

Matinas BioPharma Hldgs (MTNB) Forecast

Matinas BioPharma Hldgs (AMEX:MTNB) Stock, Quote.Headers.trade-ideas